홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Hydrazine → tert.-Butyl 2-(hydrazino)acetic acid

HRID 1180360
인쇄

반응식

HRID 1180360 반응식
O.[NH2:2][NH2:3].C([O:8][C:9](=[O:12])[CH2:10]Br)(C)(C)C.NN.N(C(O[CH2:36][C:37]1[CH:42]=CC=C[CH:38]=1)=O)[C@H](C(N[C@H](C(ON1C(=O)CCC1=O)=O)C)=O)C>>[C:37]([CH:10]([NH:2][NH2:3])[C:9]([OH:8])=[O:12])([CH3:42])([CH3:38])[CH3:36]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

5

반응물 4

HCID 9321HydrazineHCID 24654Hydrazine hydrate (1:1)HCID 79177tert-Butyl bromoacetateHCID 12876467Z-Ala-Ala-OSu

생성물 1

HCID 55280357tert.-Butyl 2-(hydrazino)acetic acid

실험 절차

The inhibitors 18, 22 and 24 were prepared as described in Scheme 2. The compound tert.-Butyl 2-(hydrazino)acetic acid was prepared from 80% hydrazine hydrate and t-butylbromoacetate according to the procedure of Niedrich, 1969. The hydrazine was coupled with Z-Ala-Ala-OSu 1 (prepared as described in Experimentals, Starting Material) to obtain the compound 14. Treatment of the t-butyl ester with TFA in dichloromethane provided the compound 15, which was converted into the compound 16 via coupling reaction with HATU, HOAt and triphenylmethylamine. Acylation with chloroacetyl chloride or bromoacetyl bromide gave the corresponding chloroacetyl and bromoacetyl derivative 17 and 21. The trityl protecting group was removed by TFA in the presence of triisopropylsilane to give the inhibitor 2-[2-(Cbz-L-Ala-L-Ala)-1-chloroacetyl)hydrazino]acetamide 18 and 22 (Method D). Treatment of 21 with benzoic acid in the presence of potassium fluoride was followed by treatment with trifluoroacetic acid (Method D) generated the benzoyloxymethylketone 24. The asparagine analogues were recognised by the protease resulting in potent inhibition. The second-order rate constant for the inactivation of legumain by the chloromethylketone (18), 139088 M−1s−1 is approximately 200 fold higher than that of the Michael acceptor inhibitors (Table 3). Whereas the bromomethylketone (22) is another potent inhibitor, the benzoyloxymethylketone (24) displays only moderate inhibition. Neither papain nor cathepsin B is inhibited by these inhibitors.

후처리

  1. customThe inhibitors 18, 22 and 24 were prepared

출처 및 근거

ORD 기록
ord-78bf758b3d364abaa361c117c30b8f46
출처 데이터셋
uspto-grants-2007_10
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07279550B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트